Newsletter Subject

OTC Morphine, APPROVED

From

freedompress.com

Email Address

news@freedompress.com

Sent On

Sat, May 11, 2024 01:01 PM

Email Preheader Text

US Market Approval - No side effects or Addiction Risk Sponsored content keeps our newsletter free.

US Market Approval - No side effects or Addiction Risk [Freedom Press](3D%3D/0d1db0d869009a3c60641c1cd4d8d1d3h?x-ew-link-index=1) Sponsored content keeps our newsletter free. We do not endorse all advertisers. Hi, By now, you have heard the news rumblings. After 10 years of testing, Conolidine "Nature's Morphine" is APPROVED to come to the US market effective immediately. As you now know, Conolidine is the most powerful natural pain reliever in the world, boasting pharmaceutical level relief with no negative effects. Remember this Harvard headline? This is just one of MANY now online. 3D/b4a91b1681728809f6c2d7dd924ea79dh?x-ew-link-index=1 [Go here to learn how Conolidine eases daily pain without side effects or addiction risk](3D/b4a91b1681728809f6c2d7dd924ea79dh?x-ew-link-index=2) Imagine a relief compound 20X the power of CBD. Imagine lowering your pain levels by 80% or 90% without any drugs or life changes. .... And at 1/10th the cost of dangerous "pain management" As of today you can access all of this without a script or even a doctor's visit. [All you have to do is visit this page to access the first Conoldine formula publicly available](3D/b4a91b1681728809f6c2d7dd924ea79dh?x-ew-link-index=3) If you hurt daily you could be minutes away from a lifetime of relief. To confirm, Conolidine is certified drug-free and legal to use in the US and all over the world. You can even travel with it. [All you have to do is visit this exclusive page dedicated to Conolidine](3D/b4a91b1681728809f6c2d7dd924ea79dh?x-ew-link-index=4) Clint Winters, Medical Scientist P.S. One last bit of info, this powerful ingredient has gone through five years of clinical testing showing a 92% relief success rate. [You can view the stunning results here](3D/b4a91b1681728809f6c2d7dd924ea79dh?x-ew-link-index=5) P.P.S. Final thought - Big Pharma is not happy about this newly public information, they could try to censor this page at any time. Above ad is sent on behalf of GDR Labs. 1360 Union Hill Rd, Alpharetta, GA, 30004. If you would like to unsubscribe from receiving offers from us, please [click here](3D/8297fe2223ea4c57f88f68ee83cc4355h?x-ew-link-index=1). c) 2024 Freedom Press. All Rights Reserved. Protected by copyright laws of the United States and treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without express written permission. Nothing in this e-mail should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. The information presented here is for public educational purposes only. MATERIAL CONNECTION DISCLOSURE: You should assume that the sender of this email has an affiliate relationship and/or another material connection to the persons or businesses mentioned in or linked to from this message and may receive commissions from purchases you make on subsequent web sites. You should never rely solely on information contained in this email to evaluate the product or service being endorsed. Always exercise due diligence before purchasing any product or service. 2810 N Church St PMB 49440 Wilmington, Delaware 19802-4447 US If you wish to opt out, click [Unsubscribe](

Marketing emails from freedompress.com

View More
Sent On

26/05/2024

Sent On

26/05/2024

Sent On

26/05/2024

Sent On

25/05/2024

Sent On

25/05/2024

Sent On

25/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.